Daily Pharma News - 31 October 2026

Welcome to today's Daily Pharma News from PharmacoLearn, your quick revision of the most important pharmaceutical, regulatory and industry developments from India and around the world. Today's edition is led by a major price relief for cancer patients in India, a global quality milestone for a Bengaluru API plant, two important United States drug approvals, a European safety review, faster biologic manufacturing in China, and a landmark HIV drug patent ruling from Russia.

NPPA cuts prices of 543 anti-cancer brands from 9 November 2026 — anti-cancer drug price control in India

The National Pharmaceutical Pricing Authority (NPPA) has revised the maximum retail prices (MRPs) of 543 anti-cancer brands, with the new prices effective from 9 November 2026. The revision follows the trade margin rationalisation for 137 non-scheduled anti-cancer drugs, under which trade margins have been capped at 30 percent. For pharmacy students, this is a textbook example of how the Drug Price Control Order (DPCO) framework and NPPA's margin-capping powers work in practice for non-scheduled formulations.

The move matters far beyond a single price list. Anti-cancer medicines are among the most expensive treatments Indian families face, and lower MRPs directly improve access and adherence for patients undergoing long-term oncology therapy. It also signals continued regulatory attention on essential and high-cost medicines, a theme that regularly appears in GPAT, Drug Inspector and pharmacy law examinations. Students should note the distinction between scheduled drugs, whose prices are fixed by ceiling price, and non-scheduled drugs, where trade margin rationalisation is the key control mechanism.

Hikal's Bengaluru API plant earns Swissmedic GMP certificate — Indian API manufacturing quality milestone

Hikal's active pharmaceutical ingredient (API) facility in Bengaluru has received a Certificate of GMP Compliance from Swissmedic, Switzerland's medicines regulator, under the EU-Switzerland Mutual Recognition Agreement. The certification follows earlier inspections by Brazil's ANVISA and Japan's PMDA, adding another major international quality endorsement for the plant. For India's pharmaceutical industry, which supplies APIs and finished formulations worldwide, such recognition strengthens the country's reputation as a trusted global manufacturing hub.

For pharmacy students, this story connects several important concepts: Good Manufacturing Practice (GMP), international regulatory inspections, and mutual recognition agreements between regulators. Bengaluru's growing pharmaceutical and biotechnology cluster in South India is increasingly significant for API production, quality assurance careers and regulatory affairs roles. A Swissmedic certificate is particularly valuable because it reflects acceptance of the facility's quality systems by one of the world's most respected regulatory authorities.

US FDA approves Sun Pharma's Ilumya for psoriatic arthritis — tildrakizumab IL-23 inhibitor approval

The United States Food and Drug Administration (US FDA) has approved Sun Pharma's Ilumya (tildrakizumab-asmn) for adults with active psoriatic arthritis, expanding the drug's use beyond its earlier psoriasis indication. The approval, granted on 30 October 2026, was supported by the Phase 3 INSPIRE-1 and INSPIRE-2 clinical trials. Ilumya is an interleukin-23 (IL-23) inhibitor, a class of biologic medicines that target a key cytokine pathway driving inflammation in psoriasis and psoriatic arthritis.

This approval is a proud moment for Indian pharmaceutical innovation on the global stage, with an Indian company securing a new US indication for a biologic medicine. For students, Ilumya is a useful case study in monoclonal antibody pharmacology: IL-23 inhibitors block the p19 subunit of interleukin-23, reducing the inflammatory cascade behind skin and joint disease. Psoriatic arthritis itself is an important clinical topic, as up to a third of psoriasis patients develop inflammatory joint disease, making early recognition and appropriate referral essential in community and clinical pharmacy practice.

FDA grants accelerated approval to Voceryq, first plasmid DNA therapy for rare airway disease

The US FDA granted accelerated approval on 30 October 2026 to Inovio Pharmaceuticals' Voceryq for adults with recurrent respiratory papillomatosis (RRP), a rare disease in which benign wart-like growths repeatedly develop in the airways, often requiring multiple surgeries. Voceryq is the first plasmid DNA-based immunotherapy approved in the United States, marking a milestone for DNA medicine technology. Because the approval is accelerated, confirmatory clinical trials will be required to verify its long-term clinical benefit.

For pharmacy students, this story introduces two important ideas at once: the accelerated approval pathway, which allows promising therapies for serious conditions to reach patients on surrogate endpoints while further evidence is gathered, and plasmid DNA immunotherapy, a platform that delivers DNA encoding disease-related antigens to stimulate an immune response. Recurrent respiratory papillomatosis is caused by human papillomavirus (HPV) types 6 and 11, linking this approval to the wider story of HPV-related disease and immunotherapy. Rare disease drug development is also a growing area for pharmacists in regulatory affairs, pharmacovigilance and clinical research.

EMA reviews Deanxit over serious neurological side-effect reports — pharmacovigilance safety review

The European Medicines Agency (EMA) has started a safety review of Lundbeck's Deanxit, a combination of flupentixol and melitracen, after reports of serious neurological and psychiatric adverse effects, including movement disorders and memory problems. The review, begun by EMA's Pharmacovigilance Risk Assessment Committee (PRAC) on 30 October 2026, is expected to reach a decision by March 2027. Deanxit is used in some countries for depression and anxiety, though it is not authorised in several major markets.

This is a live pharmacovigilance case study for pharmacy students. It shows how spontaneous adverse drug reaction reports can trigger a formal regulatory review, and how PRAC assesses the balance of benefits and risks for an established medicine. The combination itself is instructive: flupentixol is a thioxanthene antipsychotic that blocks dopamine receptors, which explains movement-related effects, while melitracen is a tricyclic antidepressant. Students should also note that regulatory decisions in Europe often influence discussions worldwide, including in India, where clinicians and regulators watch EMA and FDA safety actions closely.

China grants NMPA priority review for localised biologic manufacturing — Altruist Biologics Hangzhou facility

China's National Medical Products Administration (NMPA) has accepted and granted priority review to Altruist Biologics' application for localised manufacturing of a multinational company's biologic medicine at its Hangzhou facility. The priority review status shortens the regulatory timeline, allowing the localised production to reach Chinese patients sooner. The move reflects China's broader push to strengthen domestic biopharmaceutical manufacturing capacity and reduce dependence on imported biologics.

For Indian pharmacy students, this story is relevant on two levels. First, it illustrates how priority review and expedited pathways work outside India, paralleling mechanisms such as accelerated approvals in the US and Europe. Second, it highlights the competitive global biologics landscape: contract development and manufacturing organisations (CDMOs) are central to how complex biologic medicines are produced, and countries across Asia are investing heavily in this capacity. India, with its own strong biologics and biosimilars sector, competes directly in this space, making regulatory speed and manufacturing quality decisive advantages.

Russian court grants licence to make HIV drug cabotegravir locally — patent licensing and access to medicines

In a recent court ruling reported on 23 October 2026, a Moscow Region court ordered ViiV Healthcare and Shionogi to grant Russian manufacturer Biokhimik a non-exclusive licence for the patents covering cabotegravir, an important HIV medicine. The licence carries combined royalties of 1.75 percent, though marketing authorisation and funding arrangements remain separate steps before locally made cabotegravir can reach patients. Cabotegravir is used both for HIV treatment and as long-acting pre-exposure prophylaxis (PrEP), making it a key medicine in the global fight against HIV.

This ruling is a significant case study in pharmaceutical patent law and access to medicines, topics central to pharmacy education. Compulsory and court-ordered licensing is a recognised legal tool that balances patent holders' rights with public health needs, particularly for high-cost essential medicines. For Indian students, the parallels with India's own patent law, including compulsory licensing provisions under the Patents Act, are direct and exam-relevant. The case also underlines why long-acting injectable antiretrovirals matter: they can transform adherence for people living with HIV and for those using PrEP, compared with daily oral tablets.

Conclusion

Today's news ties together the three forces shaping modern pharmacy: affordability, quality and innovation. India's NPPA price cuts and the Russian cabotegravir ruling both show regulators and courts acting to widen access to essential medicines, while the Swissmedic certification of Hikal's Bengaluru plant and China's NMPA priority review show how manufacturing quality and regulatory speed determine who supplies the world's medicines. The FDA approvals of Ilumya and Voceryq, alongside the EMA's safety review of Deanxit, remind us that innovation and vigilance must go together — every new therapy brings promise, and every established medicine deserves continued safety monitoring. For pharmacy students, these stories are not just headlines: they are real-world examples of drug pricing, GMP, clinical trials, pharmacovigilance, patent law and regulatory pathways that appear throughout the B.Pharm and M.Pharm curriculum and in competitive examinations. Staying updated with daily pharma news builds the clinical and regulatory awareness that distinguishes a good pharmacist from a great one.

References

← All daily news